论文部分内容阅读
最近的研究表明内皮祖细胞(EPCs)有助于心血管损伤如心肌梗死(MI)、动脉粥样硬化(AS)、缺血性心脏病(IHD)、经皮腔内冠状动脉成形术(PTCA)等后的成体新生血管形成和心血管重建。EPCs移植输入可以增加血管形成及心肌细胞再生。在几种实验动物模型中EPCs可促进外周血管或心肌缺血后的血管形成和毛细血管密度及心肌修复。并且,MI后移植EPCs增强心脏功能。这表明祖细胞极有可能成为一种改进治疗这些血管疾病发生、心肌再生、防止再狭窄、抑制新生内膜过度增生的方法。现综述有关祖细胞移植术所获得的观察结果,并探讨通过药物调控如过氧化物酶体增殖因子活化受体(PPARγ)及其兴奋剂噻唑烷二酮(TZDs)等这些新的干预措施以增强EPCs功能和数量,提高其移植效果。
Recent studies have shown that endothelial progenitor cells (EPCs) contribute to cardiovascular damage such as myocardial infarction (MI), atherosclerosis (AS), ischemic heart disease (IHD), percutaneous transluminal coronary angioplasty (PTCA) ) And other adult neovascularization and cardiovascular reconstruction. Transplantation of EPCs can increase angiogenesis and cardiomyocyte regeneration. EPCs can promote peripheral blood vessels or myocardial ischemia after angiogenesis and capillary density and myocardial repair in several experimental animal models. And EPCs augmented cardiac function after MI. This shows that progenitor cells are most likely to become a way to improve the treatment of these vascular diseases, myocardial regeneration, prevent restenosis, inhibit neointimal hyperplasia method. The observations obtained on progenitor cell transplantation are reviewed and new interventions such as thiazolidinedione (TZDs), such as peroxisome proliferator-activated receptor (PPARγ) and its agonists, are explored Enhance the function and quantity of EPCs and improve their transplantation effect.